Scopus
YÖKSİS Eşleşti
Comparative effects of high-dose atorvastatin versus rosuvastatin on lipid parameters, oxidized low-density lipoprotein, and proprotein convertase subtilisin kexin 9 in acute coronary syndrome
Coronary Artery Disease · Ocak 2019
YÖKSİS Kayıtları
Comparative effects of high-dose atorvastatin versus rosuvastatin on lipid parameters, oxidized low-density lipoprotein, and proprotein convertase subtilisin kexin 9 in acute coronary syndrome
CORONARY ARTERY DISEASE · 2019 SCI-Expanded
PROFESÖR BAHADIR ÖZTÜRK →
Comparative effects of high-dose atorvastatin versus rosuvastatin on lipid parameters, oxidized low-density lipoprotein, and proprotein convertase subtilisin kexin 9 in acute coronary syndrome
CORONARY ARTERY DISEASE · 2019 SCI-Expanded
PROFESÖR BÜLENT BEHLÜL ALTUNKESER →
Comparative effects of high-dose atorvastatin versus rosuvastatin on lipid parameters, oxidized low-density lipoprotein, and proprotein convertase subtilisin kexin 9 in acute coronary syndrome
CORONARY ARTERY DISEASE · 2019 SCI-Expanded
DOÇENT MUHAMMED ULVİ YALÇIN →
Comparative effects of high-dose atorvastatin versus rosuvastatin on lipid parameters, oxidized low-density lipoprotein, and proprotein convertase subtilisin kexin 9 in acute coronary syndrome
Coronary Artery Disease · 2019 SCI-Expanded
PROFESÖR ABDULLAH TUNÇEZ →
Comparative effects of high-dose atorvastatin versus rosuvastatin on lipid parameters, oxidized low-density lipoprotein, and proprotein convertase subtilisin kexin 9 in acute coronary syndrome
Coronary Artery Disease · 2019 SCI-Expanded
PROFESÖR NAZİF AYGÜL →
Comparative effects of high-dose atorvastatin versus rosuvastatin on lipid parameters, oxidized low-density lipoprotein, and proprotein convertase subtilisin kexin 9 in acute coronary syndrome
Ovid Technologies (Wolters Kluwer Health) · 2019 SCI-Expanded
DOKTOR ÖĞRETİM ÜYESİ HÜSEYİN TEZCAN →
Makale Bilgileri
DergiCoronary Artery Disease
Yayın TarihiOcak 2019
Cilt / Sayfa30 · 285-290
Scopus ID2-s2.0-85065291745
Özet
Aim Current guidelines recommend administration of highdose statins in acute coronary syndrome (ACS). It has been reported that statins upregulate proprotein convertase subtilisin kexin 9 (PCSK9) mRNA expression and increase circulating PCSK9 levels. We aimed to compare the effects of high-dose atorvastatin and rosuvastatin on serum oxidized low-density lipoprotein (oxidized-LDL) and PCSK9 levels in statin-naive patients with ACS. Patients and methods One hundred and six patients with ACS were enrolled in this study. The patients were assigned randomly to receive atorvastatin (80 mg/day) or rosuvastatin (40 mg/day) by using a ratio of 1 : 1 in randomization. The levels of total cholesterol (TC), triglyceride, high-density lipoprotein cholesterol, LDLcholesterol, oxidized-LDL, and PCSK9 were compared between groups after a 4-week treatment. Results Our study population included 53 patients in the atorvastatin group (age: 58.13± 11.30 years, 11.32% female) and 53 patients in the rosuvastatin group (age: 59.08± 12.44 years, 15.09% female). In both groups, lipid parameters, oxidized-LDL, and PCSK9 values changed significantly according to the baseline following treatment. High-dose atorvastatin and rosuvastatin induced similar decreases in LDL-cholesterol, oxidized-LDL, and triglyceride levels and similarly increased in high-density lipoprotein cholesterol and PCSK9 levels (P>0.05). Conclusion We showed that atorvastatin and rosuvastatin treatment regimens have comparable effects on lipid parameters and PCSK9 levels in ACS patients.
Yazarlar (9)
1
Bulent Behlul Altunkeser
2
Abdullah Tunçez
3
Bahadır Öztürk
4
Hüseyin Tezcan
5
Muhammed Salih Ateş
6
Canan Yilmaz
7
Muhammed Ulvi Yalçın
8
Nazif Aygül
9
Kenan Demir
Anahtar Kelimeler
Acute coronary sydrome
Oxidized low-density lipoprotein
Proprotein convertase subtilisin kexin 9
Kurumlar
Selçuk Üniversitesi
Selçuklu Turkey
Metrikler
7
Atıf
9
Yazar
3
Anahtar Kelime